Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Liabilities and Shareholders Equity (2016 - 2025)

Seres Therapeutics' Liabilities and Shareholders Equity history spans 11 years, with the latest figure at $143.5 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 19.73% year-over-year to $143.5 million; the TTM value through Sep 2025 reached $591.3 million, down 50.74%, while the annual FY2024 figure was $139.8 million, 61.01% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $143.5 million at Seres Therapeutics, roughly flat from $143.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $406.4 million in Q2 2023 and bottomed at $139.8 million in Q4 2024.
  • The 5-year median for Liabilities and Shareholders Equity is $311.9 million (2022), against an average of $285.1 million.
  • The largest annual shift saw Liabilities and Shareholders Equity soared 176.35% in 2021 before it crashed 61.01% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $354.9 million in 2021, then decreased by 1.71% to $348.8 million in 2022, then rose by 2.81% to $358.6 million in 2023, then tumbled by 61.01% to $139.8 million in 2024, then rose by 2.62% to $143.5 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Liabilities and Shareholders Equity are $143.5 million (Q3 2025), $143.8 million (Q2 2025), and $164.2 million (Q1 2025).